Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial


Bahl A., Oudard S., Tombal B., Ozguroglu M. , Hansen S., Kocak I., ...More

ANNALS OF ONCOLOGY, vol.24, no.9, pp.2402-2408, 2013 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 9
  • Publication Date: 2013
  • Doi Number: 10.1093/annonc/mdt194
  • Title of Journal : ANNALS OF ONCOLOGY
  • Page Numbers: pp.2402-2408

Abstract

Cabazitaxel significantly improves overall survival (OS) versus mitoxantrone in patients with metastatic castration-resistant prostate cancer after docetaxel failure. We examined patient survival at 2 years and tumour-related pain with cabazitaxel versus mitoxantrone.